Niall Casey - 22 Jul 2025 Form 3 Insider Report for CARLSMED, INC.

Role
Chief IP Officer, Secretary, Director
Signature
/s/ Leonard Greenstein, as attorney-in-fact for Niall Casey
Issuer symbol
CARL on Nasdaq
Transactions as of
22 Jul 2025
Net transactions value
$0
Form type
3
Filing time
22 Jul 2025, 17:31:53 UTC
Next filing
30 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Casey Niall Chief IP Officer, Secretary, Director C/O CARLSMED, INC., 1800 ASTON AVE., SUITE 100, CARLSBAD /s/ Leonard Greenstein, as attorney-in-fact for Niall Casey 22 Jul 2025 0002077161

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CARL Common Stock 933,973 22 Jul 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CARL Stock Option (Right to Buy) 22 Jul 2025 Common Stock 112,478 $4.35 Direct F2, F4
holding CARL Series B Preferred Stock 22 Jul 2025 Common Stock 3,612 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares of common stock are reported after giving effect to the 1-for-5.58 reverse split of the Issuer's common and preferred stock effected on July 10, 2025 (the "Reverse Split").
F2 Includes 112,478 unvested stock options convertible into approximately 112,478 shares of the Issuer's common stock, which began to vest on December 15, 2024, subject to a one-year cliff, and will be fully vested on December 15, 2028. These options are reported after giving effect to the Reverse Split.
F3 Includes 3,612 shares of Series B Preferred Stock issued to the Reporting Person on April 18, 2022. Each share of Series B Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported after giving effect to the Reverse Split and on an as-converted 1-to-1 basis and have no expiration date.
F4 The exercise price has been adjusted to reflect the Reverse Split.